Rapid Communication - Journal of Clinical and Bioanalytical Chemistry (2022) Volume 6, Issue 6
Histopathological characteristics and methodologies in pharmacokinetic profiles of drug formulations.
Department of Chemistry and Biochemistry, Faculty of Science, California State University Fullerton, Fullerton
- *Corresponding Author:
- Richard Bradley
Department of Chemistry and Biochemistry, Faculty of Science
California State University Fullerton
Received: 26-Nov-2022, Manuscript No. AAACBC-22-82314; Editor assigned: 28-Nov-2022, PreQC No. AAACBC-22-82314(PQ); Reviewed: 12-Dec-2022, QC No. AAACBC-22-82314; Revised: 17-Dec-2022, Manuscript No. AAACBC-22-82314(R); Published: 24-Dec-2022, DOI: 10.35841/aacbc-6.6.129
Citation: Bradley R. Histopathological characteristics and methodologies in pharmacokinetic profiles of drug formulations. J Clin Bioanal Chem. 2022;6(6):129
A wider variety of distinct classes of therapeutic, preventative, imaging, and other agents are used in modern pharmacotherapy. These agents range in size and complexity from diatomic gases, oxygen, and nitric oxide to cellular fragments and cells themselves-natural or modified chemically or genetically. Therapeutics can be split into traditional conventional pharmaceuticals and biologicals or biotherapeutics, such as proteins, nucleic acids, and other biomolecules, in the range between these extremes
Liposomes, Nanocarriers, Oral administration.
Small molecules and biologicals both have problems getting from the administration site to the desired location of action inside the body of a patient. In order to permit or enhance distribution of some of these agents, numerous drug delivery systems (DDS; liposomes, nanocarriers, affinity drug conjugates, etc.) have been developed. Additionally, DDS themselves occasionally perform extra tasks and even have therapeutic effects. In this review, we focus on the key elements that influence how DDS behaves after being injected into an organism. The discrepancies in PK and biodistribution control mechanisms between DDS and small-molecule medications and biologics present one difficulty in characterising the in vivo behaviour of DDS. Only a brief summary of the processes governing their in vivo behaviour is given because the goal of this review is to highlight their differences from DDS rather than to provide a full description of the ADME of small molecules and biologics .
Absorption into the bloodstream, which can be influenced by both a drug's characteristics and the place of administration, is the first obstacle for medications supplied via an extravascular route to overcome before reaching the site of action. Following oral administration of small-molecule medications, the gastrointestinal (GI) tract is where absorption typically takes place. In essence, the drug must dissolve and permeate across the GI wall after dosing, together with the dosage form .
Last but not least, absorption is not normally taken into account for DDS due to the extremely low efficiency of uptake into the systemic circulation following extravascular distribution. Oral administration of nanoparticles has been the subject of numerous preclinical experiments; nonetheless, absorption is frequently inadequate due to poor penetration across the GI wall. Due to the effective uptake of resident immune cells in the lymph nodes collecting fluid draining from the injection site, bioavailability of DDS after extravascular injection (e.g., subcutaneous or intramuscular) would likely be very low; however, this may be an effective route of administration for local delivery .
The flow of medications between blood and tissues after they enter the systemic circulation plays a crucial role in regulating the therapeutic efficacy and side effects. Similar to absorption, the kinetics and mechanism of medication dispersion vary greatly amongst pharmacological classes. Small-molecule medications in particular can have a variety of distribution patterns, from being restricted to the plasma space to being dispersed throughout the entire body .
Metabolism/Elimination. Similar to the previous steps, different molecules are eliminated from the system by different methods and at varied rates. There are two main methods of small molecule removal. The relative efficacies of glomerular filtration, active secretion into the urine, and reabsorption (active and passive) from the tubules regulate renal clearance .
When the molecular mass of peptides and small-protein therapies is below the glomerular filtration threshold (60 kDa), renal clearance may be considerable. However, catabolic breakdown can take place throughout the body for proteins that are not excreted in the urine, usually after absorption into the endo-lysosomal pathway. When a protein with a high affinity for an internalising receptor is taken up through receptor-mediated endocytosis, a process known as target-mediated drug disposition can be used to increase the effectiveness of this breakdown .
For drug delivery systems, the liver, spleen, bone marrow, and lung are examples of tissues of the reticuloendothelial system (RES), which serve as the main route of elimination. Large numbers of phagocytic cells (like macrophages), which identify nanoparticles as foreign objects and effectively remove them from the bloodstream, are present in these tissues.
- Thormann W, Zhang CX, Schmutz A. Capillary electrophoresis for drug analysis in body fluids. Therapeutic drug monitoring. 1996;18(4):506-20.
- Stalcup AM, Agyei NM. Heparin: a chiral mobile-phase additive for capillary zone electrophoresis. Analytical chemistry. 1994;66(19):3054-9.
- Soichot M, Mégarbane B, Houzé P, et al. Development, validation and clinical application of a LC-MS/MS method for the simultaneous quantification of hydroxychloroquine and its active metabolites in human whole blood. Journal of pharmaceutical and biomedical analysis. 2014;100:131-7.
- Tett SE, Cutler DJ, Day RO, et al. Bioavailability of hydroxychloroquine tablets in healthy volunteers. British journal of clinical pharmacology. 1989;27(6):771-9.
- Somer M, Kallio J, Pesonen U, et al. Influence of hydroxychloroquine on the bioavailability of oral metoprolol. British journal of clinical pharmacology. 2000;49(6):549-54.